A systematic review of pharmacogenetic testing to guide antipsychotic treatment

Noushin Saadullah Khani; Georgie Hudson; Georgina Mills; Soumita Ramesh; Lauren Varney; Marius Cotic; Rosemary Abidoph; Alvin Richards-Belle; Lorena Carrascal-Laso; Manuel Franco-Martin; Benjamin Skov Kaas-Hansen; Gesche Jürgens; Barbara Barrett; Huajie Jin; Elvira Bramon

doi:10.1038/s44220-024-00240-2

A systematic review of pharmacogenetic testing to guide antipsychotic treatment

Noushin Saadullah Khani^*, Georgie Hudson, Georgina Mills, Soumita Ramesh, Lauren Varney, Marius Cotic, Rosemary Abidoph, Alvin Richards-Belle, Lorena Carrascal-Laso, Manuel Franco-Martin, Benjamin Skov Kaas-Hansen, Gesche Jürgens, Barbara Barrett, Huajie Jin, Elvira Bramon^*

^*Corresponding author for this work

Department of Intensive Care

Abstract

Pharmacogenomics could optimize antipsychotic treatment by preventing adverse drug reactions, improving treatment efficacy or relieving the cost burden on the healthcare system. Here we conducted a systematic review to investigate whether pharmacogenetic testing in individuals undergoing antipsychotic treatment influences clinical or economic outcomes. On 12 January 2024, we searched MEDLINE, EMBASE, PsycINFO and Cochrane Centrale Register of Controlled Trials. The results were summarized using a narrative approach and summary tables. In total, 13 studies were eligible for inclusion in the systematic review. The current evidence base is either in favor of pharmacogenetics-guided prescribing or showed no difference between pharmacogenetics and treatment as usual for clinical and economic outcomes. In the future, we require randomized controlled trials with sufficient sample sizes that provide recommendations for patients who take antipsychotics based on a broad, multigene panel, with consistent and comparable clinical outcomes.

Original language	English
Journal	Nature Mental Health
Volume	2
Issue number	5
Pages (from-to)	616-626
Number of pages	11
ISSN	2731-6076
DOIs	https://doi.org/10.1038/s44220-024-00240-2
Publication status	Published - 2024

Access to Document

10.1038/s44220-024-00240-2

Cite this

Saadullah Khani, N., Hudson, G., Mills, G., Ramesh, S., Varney, L., Cotic, M., Abidoph, R., Richards-Belle, A., Carrascal-Laso, L., Franco-Martin, M., Kaas-Hansen, B. S., Jürgens, G., Barrett, B., Jin, H., & Bramon, E. (2024). A systematic review of pharmacogenetic testing to guide antipsychotic treatment. Nature Mental Health, 2(5), 616-626. https://doi.org/10.1038/s44220-024-00240-2

Saadullah Khani, N, Hudson, G, Mills, G, Ramesh, S, Varney, L, Cotic, M, Abidoph, R, Richards-Belle, A, Carrascal-Laso, L, Franco-Martin, M, Kaas-Hansen, BS, Jürgens, G, Barrett, B, Jin, H & Bramon, E 2024, 'A systematic review of pharmacogenetic testing to guide antipsychotic treatment', Nature Mental Health, vol. 2, no. 5, pp. 616-626. https://doi.org/10.1038/s44220-024-00240-2

@article{f031ba4aa887469eb000a4e6496ab1a7,

title = "A systematic review of pharmacogenetic testing to guide antipsychotic treatment",

abstract = "Pharmacogenomics could optimize antipsychotic treatment by preventing adverse drug reactions, improving treatment efficacy or relieving the cost burden on the healthcare system. Here we conducted a systematic review to investigate whether pharmacogenetic testing in individuals undergoing antipsychotic treatment influences clinical or economic outcomes. On 12 January 2024, we searched MEDLINE, EMBASE, PsycINFO and Cochrane Centrale Register of Controlled Trials. The results were summarized using a narrative approach and summary tables. In total, 13 studies were eligible for inclusion in the systematic review. The current evidence base is either in favor of pharmacogenetics-guided prescribing or showed no difference between pharmacogenetics and treatment as usual for clinical and economic outcomes. In the future, we require randomized controlled trials with sufficient sample sizes that provide recommendations for patients who take antipsychotics based on a broad, multigene panel, with consistent and comparable clinical outcomes.",

author = "{Saadullah Khani}, Noushin and Georgie Hudson and Georgina Mills and Soumita Ramesh and Lauren Varney and Marius Cotic and Rosemary Abidoph and Alvin Richards-Belle and Lorena Carrascal-Laso and Manuel Franco-Martin and Kaas-Hansen, {Benjamin Skov} and Gesche J{\"u}rgens and Barbara Barrett and Huajie Jin and Elvira Bramon",

note = "{\textcopyright} The Author(s) 2024.",

year = "2024",

doi = "10.1038/s44220-024-00240-2",

language = "English",

volume = "2",

pages = "616--626",

journal = "Nature Mental Health",

issn = "2731-6076",

publisher = "Springer Nature",

number = "5",

}

TY - JOUR

T1 - A systematic review of pharmacogenetic testing to guide antipsychotic treatment

AU - Saadullah Khani, Noushin

AU - Hudson, Georgie

AU - Mills, Georgina

AU - Ramesh, Soumita

AU - Varney, Lauren

AU - Cotic, Marius

AU - Abidoph, Rosemary

AU - Richards-Belle, Alvin

AU - Carrascal-Laso, Lorena

AU - Franco-Martin, Manuel

AU - Kaas-Hansen, Benjamin Skov

AU - Jürgens, Gesche

AU - Barrett, Barbara

AU - Jin, Huajie

AU - Bramon, Elvira

PY - 2024

Y1 - 2024

N2 - Pharmacogenomics could optimize antipsychotic treatment by preventing adverse drug reactions, improving treatment efficacy or relieving the cost burden on the healthcare system. Here we conducted a systematic review to investigate whether pharmacogenetic testing in individuals undergoing antipsychotic treatment influences clinical or economic outcomes. On 12 January 2024, we searched MEDLINE, EMBASE, PsycINFO and Cochrane Centrale Register of Controlled Trials. The results were summarized using a narrative approach and summary tables. In total, 13 studies were eligible for inclusion in the systematic review. The current evidence base is either in favor of pharmacogenetics-guided prescribing or showed no difference between pharmacogenetics and treatment as usual for clinical and economic outcomes. In the future, we require randomized controlled trials with sufficient sample sizes that provide recommendations for patients who take antipsychotics based on a broad, multigene panel, with consistent and comparable clinical outcomes.

AB - Pharmacogenomics could optimize antipsychotic treatment by preventing adverse drug reactions, improving treatment efficacy or relieving the cost burden on the healthcare system. Here we conducted a systematic review to investigate whether pharmacogenetic testing in individuals undergoing antipsychotic treatment influences clinical or economic outcomes. On 12 January 2024, we searched MEDLINE, EMBASE, PsycINFO and Cochrane Centrale Register of Controlled Trials. The results were summarized using a narrative approach and summary tables. In total, 13 studies were eligible for inclusion in the systematic review. The current evidence base is either in favor of pharmacogenetics-guided prescribing or showed no difference between pharmacogenetics and treatment as usual for clinical and economic outcomes. In the future, we require randomized controlled trials with sufficient sample sizes that provide recommendations for patients who take antipsychotics based on a broad, multigene panel, with consistent and comparable clinical outcomes.

U2 - 10.1038/s44220-024-00240-2

DO - 10.1038/s44220-024-00240-2

M3 - Journal article

C2 - 38746691

SN - 2731-6076

VL - 2

SP - 616

EP - 626

JO - Nature Mental Health

JF - Nature Mental Health

IS - 5

ER -

A systematic review of pharmacogenetic testing to guide antipsychotic treatment

Abstract

Access to Document

Fingerprint

Cite this